[Pubmed] Efficacy and safety of telitacicept for myasthenia gravis in real-world practice and exploratory outcomes in th

[RSS-Bot]

Clin Immunol. 2026 Mar 3:110696. doi: 10.1016/j.clim.2026.110696. Online ahead of print.

ABSTRACT

OBJECTIVE: To assess the efficacy and safety of telitacicept in myasthenia gravis (MG), focusing on elderly patients.

METHODS: Sixteen MG patients receiving weekly telitacicept (160 mg) for 3 months were retrospectively analyzed.

RESULTS: Telitacicept significantly improved Myasthenia Gravis Activities of Daily Living (MG-ADL), from 7.31 ± 5.02 to 1.13 ± 1.20 (p < 0.001), and Quantitative Myasthenia Gravis (QMG), from 14.81 ± 7.04 to 4.75 ± 2.27 (p < 0.001). Although not statistically significant, elderly patients showed a trend toward greater reductions in MG-ADL (-5.43 vs -3.56 at 1 month, p = 0.41; -7.29 vs -5.33 at 3 months, p = 0.54) and QMG (-8.86 vs -5.33 at 1 month, p = 0.32; -11.14 vs -9.22 at 3 months, p = 0.65). Minimal symptom expression (MSE) was 81.25%, reaching 100% in elderly patients. Immunoglobulin levels (p < 0.001), CD19+ B-cell percentages (p < 0.01), autoantibody titers (p < 0.01), and corticosteroid dosage (p < 0.05) decreased significantly.

CONCLUSION: Telitacicept is a safe, effective MG add-on therapy. Elderly patients show a potential trend toward greater improvement, warranting larger studies.

PMID:41786016 | DOI:10.1016/j.clim.2026.110696


Source: https://pubmed.ncbi.nlm.nih.gov/4178601 ... t6+133c1fe